Stakisaitis Donatas, Didziapetriene Janina, Maciulaitis Romaldas, Tschaika Marina
Institute of Oncology, Vilnius University, Santariskiu 1, 2000 Vilnius, Lithuania.
Medicina (Kaunas). 2004;40(1):9-15.
Renal tubular acidosis (RTA) more frequently develops in case of chronic diseases of inflammatory-immunological origin. RTA is well known to be associated with chronic liver disease (CLD), with nephrolithiasis, common cases of RTA occur among cancer patients. Abnormalities in the expression or function of band 3 in cell membrane may play a role in the pathogenesis of RTA. Cl-/HCO3- anion exchanger (AE2) is an isoform of band 3 protein, which is expressed in cell membranes of organs such as liver cells and kidney endothelium. There are reports on downregulated AE2 immunoreactivity in the liver of patients with chronic liver diseases and in the kidney tubular tissue of patients with RTA. The proteolytic damage of cell membrane band 3 in tissues could be related to inflammatory-immunological processes. Another important factor able to disturb the band 3 function is medicinal products used in the treatment of certain pathologies. The active substance of a drug itself may have a direct effect on this protein or trigger a pathological process. In such cases ADR can take place and may be evaluated as such. Acid-base disturbances, notably metabolic acidosis, are a serious complication of drug treatment. Reduced AE2 expression or its changed activity (congenital or acquired) could be related with alterations of intracellular pH. This could lead to antigenic changes and autoimmunity. The derangement of band 3 function in organ cell membrane could act as a factor which creates an "acidotic environment" for organ cells. Such circumstances could be the reason for unsuccessful treatment or determine resistance of tumor treatment. The understanding of the mechanisms of RTA development, early diagnostics, and knowledge of the drugs that can cause RTA, are of particular practical significance.
肾小管酸中毒(RTA)在炎症 - 免疫源性慢性疾病中更易发生。众所周知,RTA与慢性肝病(CLD)、肾结石有关,在癌症患者中也常见RTA病例。细胞膜上带3蛋白的表达或功能异常可能在RTA的发病机制中起作用。Cl⁻/HCO₃⁻阴离子交换蛋白(AE2)是带3蛋白的一种同工型,在肝细胞和肾内皮等器官的细胞膜中表达。有报道称,慢性肝病患者肝脏和RTA患者肾小管组织中AE2免疫反应性下调。组织中细胞膜带3蛋白的蛋白水解损伤可能与炎症 - 免疫过程有关。另一个能够干扰带3蛋白功能的重要因素是用于治疗某些疾病的药物。药物的活性物质本身可能对该蛋白有直接作用或引发病理过程。在这种情况下可能会发生药物不良反应(ADR)并可如此评估。酸碱紊乱,尤其是代谢性酸中毒,是药物治疗的严重并发症。AE2表达降低或其活性改变(先天性或获得性)可能与细胞内pH值的改变有关。这可能导致抗原性变化和自身免疫。器官细胞膜中带3蛋白功能紊乱可能是为器官细胞创造“酸性环境”的一个因素。这种情况可能是治疗失败的原因或决定肿瘤治疗耐药性的因素。了解RTA的发生机制、早期诊断以及可能导致RTA的药物知识具有特别重要的实际意义。